ADMA Biologics, Inc. (ADMA) Balance Sheet

NASDAQ: ADMAAssets, liabilities, debt and equity over 10 years.

ADMA balance sheet, 2025

December 31, 2025 · U.S. dollars

$624.2M assets = $146.9M liabilities + $477.3M equity

What it owns$624.2MCash & ST investments: $87.6M (14.0%)Cash & ST investments$87.6M · 14%Receivables: $158.4M (25.4%)Receivables$158.4M · 25%Inventory: $206.5M (33.1%)Inventory$206.5M · 33%Other current: $14.0M (2.2%)PP&E: $71.7M (11.5%)PP&E$71.7M · 11%Goodwill & intangibles: $4.2M (0.7%)Other non-current: $81.9M (13.1%)Other non-current$81.9M · 13%=How it is financed$624.2MCurrent liabilities: $69.5M (11.1%)Current liabilities $69.5MLong-term debt: $69.3M (11.1%)Long-term debt $69.3MOther LT liabilities: $8.1M (1.3%)Shareholders’ equity: $477.3M (76.5%)Shareholders’ equity$477.3M · 76%

Both columns are drawn to the same scale: what ADMA owns equals what it owes plus shareholders’ equity. Hover a block for its value.

ADMA financial health

Current ratio6.71
Comfortable · current assets cover current liabilities 6.71×
Debt / equity0.17
Low leverage · $0.17 of debt for each $1 of equity
Equity / assets76.5%
Equity-funded · of assets funded by shareholders
Cash / debt109.7%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.7%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

ADMA balance sheet trends, 2016–2025

ADMA Biologics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$23.7M2016$624.2M2025+43.8%/yr
Total liabilities$28.1M2016$146.9M2025+20.2%/yr
Shareholders’ equity−$4.5M2016$477.3M2025—
Cash & short-term investments$15.3M2016$87.6M2025+21.4%/yr
Total debt$20.3M2016$79.9M2025+16.5%/yr
Net cash (debt)−$5.0M2016$7.7M2025+$12.7M
Working capital$10.4M2016$397.0M2025+$386.5M
Book value per share$0.442018$1.952025+23.8%/yr
Current ratio1.9320166.712025+4.78
Debt / equity1.0720170.172025−0.90
Shares outstanding45.2M2018244.9M2025+27.3%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

ADMA assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

ADMA liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

ADMA debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

ADMA balance sheet

ADMA Biologics, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$87.6M$103.1M$51.4M$86.5M$51.1M$55.9M$26.8M$22.8M$43.1M$15.3M
Cash & equivalents$87.6M$103.1M$51.4M$86.5M$51.1M$55.9M$26.8M$22.8M$43.1M$9.9M
Short-term investments————————$1.5M$5.4M
Receivables$158.4M$50.0M$27.4M$15.5M$28.6M$13.2M$3.5M$1.4M$3.9M$1.0M
Inventory$206.5M$170.2M$172.9M$163.3M$124.7M$81.5M$53.1M$18.6M$12.6M$5.0M
Other current assets$14.0M$8.0M$5.3M$5.1M$4.3M$3.0M$2.5M$1.8M$3.6M$313,914
Total current assets$466.5M$331.4M$257.0M$270.4M$208.7M$153.7M$85.8M$44.5M$63.2M$21.7M
Property, plant & equipment (net)$71.7M$63.3M$63.5M$68.7M$58.2M$45.9M$33.0M$30.1M$30.5M$2.0M
Goodwill & intangible assets$4.2M$4.0M$4.0M$4.5M$5.3M$6.0M$6.7M$7.5M$8.4M$0
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$81.9M$89.9M$4.7M$4.8M$4.1M$2.1M$1.6M$6.7M$6.0M$27,163
Total assets$624.2M$488.7M$329.2M$348.5M$276.3M$207.7M$127.1M$88.9M$108.0M$23.7M
Liabilities
Accounts payable$22.5M$20.2M$15.7M$13.2M$12.4M$11.1M$9.2M$5.9M$5.9M$2.6M
Short-term debt$3.9M$1.2M$1.0M$905,000$591,084$365,682$229,073$29,983$3.3M$6.1M
Deferred revenue$1.4M$143,000$182,000$143,000$142,834$142,834$142,834$142,834$142,834$145,154
Total current liabilities$69.5M$55.5M$49.8M$39.3M$30.4M$19.9M$14.0M$9.6M$9.4M$11.2M
Long-term debt$69.3M$72.3M$130.6M$142.8M$94.9M$93.0M$69.6M$29.3M$28.1M$12.3M
Lease obligations$7.7M$9.8M$10.8M$11.6M$8.1M$4.7M$1.3M$119,080—$19,697
Other long-term liabilities$8.1M$11.8M$13.6M$14.4M$9.8M$6.5M$17.3M$30.2M$30.1M$4.6M
Total liabilities$146.9M$139.7M$194.0M$196.5M$135.1M$119.4M$100.9M$69.1M$67.7M$28.1M
Shareholders' equity
Common stock & paid-in capital$24,000$24,000$23,000$22,000$19,581$10,490$5,932$4,635$4,532$1,289
Retained earnings (deficit)−$161.7M−$308.6M−$506.3M−$478.0M−$412.1M−$340.5M−$264.7M−$216.4M−$150.7M−$106.9M
Treasury stock————————$0$0
Accumulated other comprehensive income———$0——−$5.7M−$3.4M−$1.3M−$2.2M
Minority interest————————$0$0
Total shareholders' equity$477.3M$349.0M$135.2M$152.0M$141.2M$88.2M$26.2M$19.8M$40.3M−$4.5M
Key figures
Total debt$79.9M$82.1M$141.4M$154.4M$102.9M$97.7M$84.7M$44.2M$43.0M$20.3M
Net cash (debt)$7.7M$21.0M−$90.1M−$67.9M−$51.8M−$41.7M−$58.0M−$21.5M$136,720−$5.0M
Working capital$397.0M$275.9M$207.2M$231.1M$178.4M$133.8M$71.8M$34.9M$53.7M$10.4M
Tangible book value$473.2M$345.0M$131.2M$147.4M$135.9M$82.3M$19.5M$12.2M$32.0M−$4.5M
Book value per share$1.95$1.43$0.60$0.77$1.01$1.02$0.48$0.44——
Shares outstanding244.9M243.3M224.0M197.9M139.6M86.1M54.3M45.2M——
Current ratio6.715.975.166.896.877.716.124.636.691.93
Quick ratio3.542.761.582.602.623.472.152.514.981.45
Debt / equity0.170.241.051.020.731.113.232.241.07—
Equity / assets76.5%71.4%41.1%43.6%51.1%42.5%20.6%22.2%37.3%−18.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 25, 2026); data from EODHD.

ADMA financial position

At the end of fiscal 2025 (December 31, 2025), ADMA Biologics had total assets of $624.2 million (up 27.7% from a year earlier), total liabilities of $146.9 million and shareholders' equity of $477.3 million. It held $87.6 million in cash and short-term investments against $79.9 million of debt, a net cash position of $7.7 million. Its current ratio was 6.71. In the latest quarter (ended June 30, 2026) total assets were $684.2 million and equity $408.2 million.

Related: ADMA income statement, ADMA cash flow statement, ADMA key metrics. See the ADMA stock overview for the latest quote and news.

ADMA balance sheet FAQ

What are ADMA Biologics's total assets?

ADMA Biologics reported total assets of $624.2 million at the end of fiscal 2025 (December 31, 2025), compared with $488.7 million a year earlier.

How much debt does ADMA Biologics have?

ADMA Biologics had $79.9 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.17.

How much cash does ADMA Biologics have?

ADMA Biologics held $87.6 million in cash and short-term investments at the end of fiscal 2025; with $79.9 million of debt that is net cash of $7.7 million.

What is ADMA Biologics's book value?

ADMA Biologics's shareholders' equity (book value) was $477.3 million at the end of fiscal 2025, or $1.95 per share.

What is ADMA Biologics's current ratio?

ADMA Biologics had current assets of $466.5 million and current liabilities of $69.5 million, a current ratio of 6.71 (it can cover its short-term obligations).

How much goodwill does ADMA Biologics have?

ADMA Biologics carried $4.2 million of goodwill and intangible assets, 0.7% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet